Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2011 Feb 15:342:d548.
doi: 10.1136/bmj.d548.

Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data

C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC); Frances Wensley, Pei Gao, Stephen Burgess, Stephen Kaptoge, Emanuele Di Angelantonio, Tina Shah, James C Engert, Robert Clarke, George Davey-Smith, Børge G Nordestgaard, Danish Saleheen, Nilesh J Samani, Manjinder Sandhu, Sonia Anand, Mark B Pepys, Liam Smeeth, John Whittaker, Juan Pablo Casas, Simon G Thompson, Aroon D Hingorani, John Danesh
Collaborators
Meta-Analysis

Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data

C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) et al. BMJ. .

Abstract

Objective: To use genetic variants as unconfounded proxies of C reactive protein concentration to study its causal role in coronary heart disease.

Design: Mendelian randomisation meta-analysis of individual participant data from 47 epidemiological studies in 15 countries.

Participants: 194 418 participants, including 46 557 patients with prevalent or incident coronary heart disease. Information was available on four CRP gene tagging single nucleotide polymorphisms (rs3093077, rs1205, rs1130864, rs1800947), concentration of C reactive protein, and levels of other risk factors.

Main outcome measures: Risk ratios for coronary heart disease associated with genetically raised C reactive protein versus risk ratios with equivalent differences in C reactive protein concentration itself, adjusted for conventional risk factors and variability in risk factor levels within individuals.

Results: CRP variants were each associated with up to 30% per allele difference in concentration of C reactive protein (P<10(-34)) and were unrelated to other risk factors. Risk ratios for coronary heart disease per additional copy of an allele associated with raised C reactive protein were 0.93 (95% confidence interval 0.87 to 1.00) for rs3093077; 1.00 (0.98 to 1.02) for rs1205; 0.98 (0.96 to 1.00) for rs1130864; and 0.99 (0.94 to 1.03) for rs1800947. In a combined analysis, the risk ratio for coronary heart disease was 1.00 (0.90 to 1.13) per 1 SD higher genetically raised natural log (ln) concentration of C reactive protein. The genetic findings were discordant with the risk ratio observed for coronary heart disease of 1.33 (1.23 to 1.43) per 1 SD higher circulating ln concentration of C reactive protein in prospective studies (P=0.001 for difference).

Conclusion: Human genetic data indicate that C reactive protein concentration itself is unlikely to be even a modest causal factor in coronary heart disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Associations of four principal single nucleotide polymorphisms (SNP) related to C reactive protein with various characteristics in individuals free from known coronary heart disease at time of measurement. Estimates presented are based on random effects meta-analysis of study specific associations of each SNP with panel of risk factors, adjusted, where appropriate, for ethnicity. Per allele model corresponds to association per addition of risk allele for each SNP
None
Fig 2 Estimates of association of each single nucleotide polymorphism with ln concentrations of C reactive protein and risk of coronary heart disease (CHD). *Frequency of allele for increased concentrations of circulating ln C reactive protein (that is, risk allele). Associations presented per additional copy of risk allele. †For associations between single nucleotide polymorphism and coronary heart disease, studies with <10 cases or <50 participants were excluded from analyses. Study specific estimates stratified, where appropriate, by sex, ethnicity, and trial arm and combined with random effects models. Maximum available data on genetic variants, circulating C reactive protein, and coronary heart disease used for analyses; sensitivity analyses restricted to participants with data on C reactive protein single nucleotide polymorphisms, circulating C reactive protein, and coronary heart disease did not differ from current analyses. Fig C in appendix 3 on bmj.com shows study specific associations between single nucleotide polymorphism and C reactive protein and coronary heart disease for each single nucleotide polymorphism
None
Fig 3 Estimates of association of each haplotype with ln concentrations of CRP and risk of coronary heart disease. *Based on seven haplotypes and therefore do not add up to 1. Haplotypes 6 and 7 excluded because they represent individuals for whom it was not possible to assign to primary haplotypes because of missing data in rs3093077 and rs1800947. See table A in appendix 1, fig F in appendix 3, and appendix 5 for details of these haplotypes and explanation of methods. Additive haplotype model was used to estimate effect of each haplotype relative to two copies of haplotype 1. See appendix 5 for details of this model. Data limited to populations of European descent, for which it was possible to assign haplotypes based on linkage disequilibrium information between single nucleotide polymorphisms (see appendix 5). Studies with <10 cases or <50 participants excluded. Study specific estimates were stratified, where appropriate, by sex, ethnicity, and trial arm and combined with multivariate random effects meta-analysis. Data available on up to 25 960 cases and up to 139 251 participants of European descent from 33 studies. Fig G in appendix 3 shows study specific associations between haplotype and C reactive protein and coronary heart disease for each haplotype
None
Fig 4 Estimates of association of circulating concentrations and genetically raised concentrations of C reactive protein (CRP) with risk of coronary heart disease (CHD). *Corrected for regression dilution in C reactive protein and potential confounding factors.
See this image and copyright information in PMC

Comment in

Similar articles

  • Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk.
    Nimptsch K, Aleksandrova K, Boeing H, Janke J, Lee YA, Jenab M, Bueno-de-Mesquita HB, Jansen EH, Tsilidis KK, Trichopoulou A, Weiderpass E, Wu C, Overvad K, Tjønneland A, Boutron-Ruault MC, Dossus L, Racine A, Kaaks R, Canzian F, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Johansson A, Van Guelpen B, Khaw KT, Wareham N, Peeters PH, Quirós JR, Venceslá García A, Molina-Montes E, Dorronsoro M, Chirlaque MD, Barricarte Gurrea A, Key TJ, Duarte-Salles T, Stepien M, Gunter MJ, Riboli E, Pischon T. Nimptsch K, et al. Int J Cancer. 2015 Mar 1;136(5):1181-92. doi: 10.1002/ijc.29086. Epub 2014 Jul 28. Int J Cancer. 2015. PMID: 25043606 Free PMC article. Clinical Trial.
  • Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.
    Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Elliott P, et al. JAMA. 2009 Jul 1;302(1):37-48. doi: 10.1001/jama.2009.954. JAMA. 2009. PMID: 19567438 Free PMC article.
  • Association of plasma C-reactive protein with ischaemic stroke: a Mendelian randomization study.
    Zhang X, Wang A, Zhang J, Singh M, Liu D, Zuo Y, Wu L, Song M, Wang W, Feigin V, Wang Y, Zheng D. Zhang X, et al. Eur J Neurol. 2020 Mar;27(3):565-571. doi: 10.1111/ene.14113. Epub 2019 Nov 26. Eur J Neurol. 2020. PMID: 31692152
  • Evaluating the causal relevance of diverse risk markers: horizontal systematic review.
    Kuper H, Nicholson A, Kivimaki M, Aitsi-Selmi A, Cavalleri G, Deanfield JE, Heuschmann P, Jouven X, Malyutina S, Mayosi BM, Sans S, Thomsen T, Witteman JC, Hingorani AD, Lawlor DA, Hemingway H. Kuper H, et al. BMJ. 2009 Nov 5;339:b4265. doi: 10.1136/bmj.b4265. BMJ. 2009. PMID: 19892791 Free PMC article. Review.
  • C-reactive protein and coronary heart disease: all said--is not it?
    Strang F, Schunkert H. Strang F, et al. Mediators Inflamm. 2014;2014:757123. doi: 10.1155/2014/757123. Epub 2014 Apr 7. Mediators Inflamm. 2014. PMID: 24808639 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95. - PubMed
    1. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12. - PMC - PubMed
    1. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40. - PMC - PubMed
    1. De Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982;156:230-42. - PMC - PubMed
    1. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999;145:375-9. - PubMed

Publication types

Substances